ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,303.27
      0.12%
      US Tech 100
      18,064.80
      -0.08%
      Dow Jones
      40,003.59
      0.34%
      Brent Oil
      83.76
      0.67%
      Bitcoin
      67,037.40
      2.76%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Syros Pharmaceuticals Inc (SYRS)

      7. Syros Pharmaceuticals Inc (SYRS) News

      SYRS

      Syros Pharmaceuticals (SYRS)

      Syros Pharmaceuticals Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:SYRS
      DateTimeSourceHeadlineSymbolCompany
      3:00PMiHub NewswireFeaturedMusic Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements
      05/14/20247:30AMBusiness WireSyros Reports First Quarter 2024 Financial Results and Provides a Corporate UpdateNASDAQ:SYRSSyros Pharmaceuticals Inc
      05/14/20246:42AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SYRSSyros Pharmaceuticals Inc
      05/07/20249:00AMBusiness WireSyros to Participate in Upcoming Investor ConferencesNASDAQ:SYRSSyros Pharmaceuticals Inc
      05/07/20247:00AMBusiness WireSyros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024NASDAQ:SYRSSyros Pharmaceuticals Inc
      04/09/20247:00AMBusiness WireSyros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpressionNASDAQ:SYRSSyros Pharmaceuticals Inc
      04/02/20244:30PMBusiness WireSyros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:SYRSSyros Pharmaceuticals Inc
      03/27/20247:30AMBusiness WireSyros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate UpdateNASDAQ:SYRSSyros Pharmaceuticals Inc
      03/27/20246:57AMIH Market NewsU.S. Stock Index Futures Point to a Rebound, Oil See Declines in Early TradingNASDAQ:SYRSSyros Pharmaceuticals Inc
      03/25/20247:00AMBusiness WireSyros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 TrialNASDAQ:SYRSSyros Pharmaceuticals Inc
      03/20/20247:00AMBusiness WireSyros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024NASDAQ:SYRSSyros Pharmaceuticals Inc
      02/27/20247:00AMBusiness WireSyros to Participate in TD Cowen 44th Annual Health Care ConferenceNASDAQ:SYRSSyros Pharmaceuticals Inc
      02/14/20248:56PMEdgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:SYRSSyros Pharmaceuticals Inc
      02/13/20248:22PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SYRSSyros Pharmaceuticals Inc
      02/13/20247:02PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SYRSSyros Pharmaceuticals Inc
      02/13/20246:59PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SYRSSyros Pharmaceuticals Inc
      01/08/20247:06AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SYRSSyros Pharmaceuticals Inc
      01/08/20247:00AMBusiness WireSyros Highlights Anticipated 2024 Milestones to Deliver on the Value of TamibaroteneNASDAQ:SYRSSyros Pharmaceuticals Inc
      01/02/20244:15PMEdgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:SYRSSyros Pharmaceuticals Inc
      12/26/20235:19PMEdgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:SYRSSyros Pharmaceuticals Inc
      12/19/20234:59PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SYRSSyros Pharmaceuticals Inc
      12/19/20234:53PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SYRSSyros Pharmaceuticals Inc
      12/19/20237:27AMBusiness WireSyros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded WarrantsNASDAQ:SYRSSyros Pharmaceuticals Inc
      12/14/20234:24PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SYRSSyros Pharmaceuticals Inc
      12/12/20234:12PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SYRSSyros Pharmaceuticals Inc
      12/08/20234:23PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SYRSSyros Pharmaceuticals Inc
      12/06/20234:00PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SYRSSyros Pharmaceuticals Inc
      12/06/20237:05AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SYRSSyros Pharmaceuticals Inc
      12/06/20237:00AMBusiness WireSyros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and AzacitidineNASDAQ:SYRSSyros Pharmaceuticals Inc
      12/05/20235:28PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SYRSSyros Pharmaceuticals Inc
       Showing the most relevant articles for your search:NASDAQ:SYRS

      Your Recent History

      LATK
      BUSDUSDT
      Binance USD
      DOWI
      DJCIAGCT
      DJ Commodity Index Agric...
      Delayed Upgrade Clock